Registrer deg | Logg på | FAQ      [?] 
Recent | Unread | Search | Authors | Tags | Export

pjaspers library [271 articles]

Nye artikler sendt til pjaspers bibliotek.
  • Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis.
    Bioessays, Vol. 29, No. 6. (16 May 2007), pp. 558-565.
    by David J J Riese, Richard M M Gallo, Jeffrey Settleman
    posted to egfr mutant review by pjasper on 2007-05-22 20:38:16 as **
  • ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.
    Proc Natl Acad Sci U S A, Vol. 102, No. 10. (8 March 2005), pp. 3788-3793.
    by JA Engelman, PA Jänne, C Mermel, J Pearlberg, T Mukohara, C Fleet, K Cichowski, BE Johnson, LC Cantley
    posted to akt erbb3 inhibitor iressa nsclc by pjasper on 2007-05-22 18:40:08 as **
  • Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
    J Clin Invest, Vol. 116, No. 10. (October 2006), pp. 2695-2706.
    by JA Engelman, T Mukohara, K Zejnullahu, E Lifshits, AM Borrás, CM Gale, GN Naumov, BY Yeap, E Jarrell, J Sun, S Tracy, X Zhao, JV Heymach, BE Johnson, LC Cantley, PA Jänne
    posted to egfr h3255 mutant resistance by pjasper on 2007-05-10 21:01:12 as ***** along with 2 people jyuh klu
  • Features of selective kinase inhibitors.
    Chem Biol, Vol. 12, No. 6. (June 2005), pp. 621-637.
    by ZA Knight, KM Shokat
    posted to inhibitor review by pjasper on 2007-05-10 20:55:43 as ***** along with 3 people seancutler Yanno anwazo
  • Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
    PLoS Med, Vol. 2, No. 3. (March 2005)
    by W Pao, VA Miller, KA Politi, GJ Riely, R Somwar, MF Zakowski, MG Kris, H Varmus
    posted to egfr iressa mutant resistance t790m tarceva by pjasper on 2007-05-10 20:41:10 as *****
  • Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Cancer Res, Vol. 61, No. 24. (15 December 2001), pp. 8887-8895.
    by SL Moulder, FM Yakes, SK Muthuswamy, R Bianco, JF Simpson, CL Arteaga
    posted to egfr erbb2 inactive_dimer iressa by pjasper on 2007-05-10 20:38:57 as *****
  • ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
    Clin Cancer Res, Vol. 9, No. 4. (April 2003), pp. 1274-1283.
    by J Anido, P Matar, J Albanell, M Guzmán, F Rojo, J Arribas, S Averbuch, J Baselga
    posted to egfr erbb2 erbb3 inactive_dimer iressa by pjasper on 2007-05-10 20:36:31 as *****
  • Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site.
    J Biol Chem, Vol. 272, No. 37. (12 September 1997), pp. 23247-23254.
    by CL Arteaga, TT Ramsey, LK Shawver, CA Guyer
    posted to egfr erbb2 inactive_dimer inhibitor by pjasper on 2007-05-10 20:34:56 as *****
  • Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.
    Cancer Res, Vol. 61, No. 15. (1 August 2001), pp. 5790-5795.
    by RB Lichtner, A Menrad, A Sommer, U Klar, MR Schneider
    posted to egfr inhibitor by pjasper on 2007-05-10 20:30:15 as *****
  • HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Cancer Res, Vol. 65, No. 10. (15 May 2005), pp. 4253-4260.
    by A Hirata, F Hosoi, M Miyagawa, S Ueda, S Naito, T Fujii, M Kuwano, M Ono
    posted to egfr erbb2 inhibitor iressa nsclc by pjasper on 2007-05-10 19:52:18 as ***** along with 1 person js229
  • Insulin-like growth factor-I (IGF-I) induces epidermal growth factor receptor transactivation and cell proliferation through reactive oxygen species.
    Free Radic Biol Med, Vol. 42, No. 11. (1 June 2007), pp. 1651-1660.
    by D Meng, X Shi, BH Jiang, J Fang
    posted to igf by pjasper on 2007-05-08 21:03:55 as ** along with 1 person jyuh
  • The E3 ligase Aip4/Itch ubiquitinates and targets ErbB-4 for degradation.
    FASEB J (26 April 2007)
    by Jasminka Omerovic, Laura Santangelo, Eleonora Maria-Rosaria M Puggioni, Jordan Marrocco, Claudia Dall'armi, Camilla Palumbo, Francesca Belleudi, Lucia Di Marcotullio, Luigi Frati, Maria-Rosaria R Torrisi, Gianni Cesareni, Alberto Gulino, Maurizio Alimandi
    posted to degradation erbb4 by pjasper on 2007-05-08 21:03:27 as **
  • MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling.
    Science (26 April 2007)
    by Jeffrey A A Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh O Park, Neal Lindeman, Christopher-Michael M Gale, Xiaojun Zhao, James Christensen, Takayuki Kosaka, Alison J J Holmes, Andrew M M Rogers, Federico Cappuzzo, Tony Mok, Charles Lee, Bruce E E Johnson, Lewis C C Cantley, Pasi A A Jänne
    posted to erbb3 met by pjasper on 2007-05-08 21:02:22 as ** along with 3 people and 1 group julius cwchen jackjackjjj SysbioMPI-TCells
  • The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
    Oncogene, Vol. aop, No. current.
    by MM Moasser
    posted to erbb2 review by pjasper on 2007-05-08 21:00:53 as ** along with 1 person jyuh
  • Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non-small Cell Lung Cancer Cells to Treatment with Gefitinib.
    Clin Cancer Res, Vol. 13, No. 9. (1 May 2007), pp. 2795-2803.
    by Floriana Morgillo, Woo-Young Y Kim, Edward S S Kim, Fortunato Ciardiello, Waun Ki K Hong, Ho-Young Y Lee
    posted to igf by pjasper on 2007-05-08 21:00:26 as **
  • Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma
    British Journal of Cancer, Vol. aop, No. current. (24 April 2007)
    by Y Lemos-Gonzalez, FJ Rodriguez-Berrocal, OJ Cordero, C Gomez, Paez
    posted to egf ligand nsclc by pjasper on 2007-05-08 20:59:01 as **
  • Erlotinib, an Effective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Induces p27KIP1 Upregulation and Nuclear Translocation in Association with Cell Growth Inhibition and Cell Cycle Arrest in Human Non-Small Cell Lung Cancer Cell Lines.
    Mol Pharmacol (24 April 2007)
    by Yi-He H Ling, Tianhong Li, Ziqiang Yuan, Missak Haigentz Jr, Thomas K K Weber, Roman Perez-Soler
    posted to inhibito nsclc p27 tarceva by pjasper on 2007-05-08 20:57:30 as **
  • Cross Talk between c-Met and Epidermal Growth Factor Receptor during Retinal Pigment Epithelial Wound Healing.
    Invest Ophthalmol Vis Sci, Vol. 48, No. 5. (May 2007), pp. 2242-2248.
    by KP Xu, FS Yu
    posted to egfr met by pjasper on 2007-05-08 20:55:53 as **
  • Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells.
    Neoplasia, Vol. 9, No. 4. (April 2007), pp. 341-348.
    by KA Cengel, KR Voong, S Chandrasekaran, L Maggiorella, TB Brunner, E Stanbridge, GD Kao, WG McKenna, EJ Bernhard
    posted to igf by pjasper on 2007-05-08 20:55:26 as **
  • T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies
    Cancer Immunology, Immunotherapy
    by Greta Garrido, Pablo Lorenzano, Belinda Sánchez, Irene Beausoleil, Daniel Alonso, Rolando Pérez, Luis Fernández
    posted to c225 cell egfr inhibitor t by pjasper on 2007-05-08 20:52:25 as **
  • Gefitinib-sensitive EGFR lacking residues 746-750 exhibits hypophosphorylation at tyrosine residue 1045, hypoubiquitination, and impaired endocytosis.
    DNA Cell Biol, Vol. 26, No. 3. (March 2007), pp. 178-185.
    by M Furukawa, I Nagatomo, T Kumagai, T Yamadori, R Takahashi, M Yoshimura, T Yoneda, Y Takeda, S Goya, H Matsuoka, T Kijima, M Yoshida, T Osaki, I Tachibana, MI Greene, I Kawase
    posted to activation egfr internalization mutant by pjasper on 2007-05-08 20:51:55 as **
  • Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
    Mol Cancer Res, Vol. 5, No. 4. (April 2007), pp. 393-401.
    by M Maegawa, K Takeuchi, E Funakoshi, K Kawasaki, K Nishio, N Shimizu, F Ito
    posted to c225 egfr erbb2 erbb3 inhibitor nsclc by pjasper on 2007-05-08 20:50:27 as **
  • Abi-1 forms an epidermal growth factor-inducible complex with Cbl: Role in receptor endocytosis.
    Cell Signal (22 February 2007)
    by Barbara E E Tanos, Ann Marie M Pendergast
    posted to abi-1 cbl egfr internalization by pjasper on 2007-05-08 20:46:50 as **
  • The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer.
    Bioorg Med Chem Lett (19 March 2007)
    by Blaise Lippa, Goss S S Kauffman, Joel Arcari, Tricia Kwan, Jinshan Chen, William Hungerford, Samit Bhattacharya, Xumiao Zhao, Courtney Williams, Jun Xiao, Leslie Pustilnik, Chunyan Su, James D D Moyer, Ling Ma, Mary Campbell, Stefanus Steyn
    posted to erbb2 inhibitor by pjasper on 2007-05-08 20:46:17 as **
  • Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Oncologist, Vol. 12, No. 3. (March 2007), pp. 325-330.
    by LV Sequist
    posted to 2ndgeneration egfr inhibitor nsclc review by pjasper on 2007-05-08 20:37:49 as **
  • Unligated Epidermal Growth Factor Receptor Forms Higher Order Oligomers within Microclusters on A431 Cells That Are Sensitive to Tyrosine Kinase Inhibitor Binding.
    Biochemistry, Vol. 46, No. 15. (17 April 2007), pp. 4589-4597.
    by AH Clayton, ML Tavarnesi, TG Johns
    posted to a431 egfr oligomer structure by pjasper on 2007-05-08 19:12:05 as **
  • The Cbl-interacting protein TULA inhibits dynamin-dependent endocytosis.
    Exp Cell Res, Vol. 313, No. 8. (1 May 2007), pp. 1696-1709.
    by V Bertelsen, K Breen, K Sandvig, E Stang, IH Madshus
    posted to cbl egfr internalization tula by pjasper on 2007-05-08 19:11:19 as **
  • Structure-based mutagenesis of the substrate-recognition domain of Nrdp1/FLRF identifies the binding site for the receptor tyrosine kinase ErbB3.
    Protein Sci, Vol. 16, No. 4. (April 2007), pp. 654-661.
    by S Bouyain, DJ Leahy
    posted to erbb3 structure by pjasper on 2007-05-08 19:10:40 as ** along with 1 person and 1 group cursonivel1 cursonivel1
  • Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival.
    Br J Cancer, Vol. 96 Suppl (2007)
    by HW Lo, MC Hung
    posted to egfr nucleus by pjasper on 2007-05-08 19:08:25 as **
  • Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): What have we learned so far?
    Cancer Treat Rev (15 March 2007)
    by Barbara Fischer, Marin Marinov, Alexandre Arcaro
    posted to inhibitor review sclc by pjasper on 2007-05-08 19:05:26 as **
  • Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility.
    Mol Cancer Res, Vol. 5, No. 3. (March 2007), pp. 283-293.
    by AB Larsen, MW Pedersen, MT Stockhausen, MV Grandal, B van Deurs, HS Poulsen
    posted to egfr epha2 by pjasper on 2007-05-08 19:04:25 as **
  • Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer.
    Cancer Res, Vol. 67, No. 6. (15 March 2007), pp. 2420-2424.
    by M Bentires-Alj, BG Neel
    posted to breast erbb2 phosphatase by pjasper on 2007-05-08 19:03:15 as ** along with 1 person klu
  • The EGF receptor Hokey-Cokey.
    Cancer Cell, Vol. 11, No. 3. (March 2007), pp. 209-211.
    by D Niculescu-Duvaz, S Whittaker, C Springer, R Marais
    posted to egfr review structure by pjasper on 2007-05-08 19:02:23 as **
  • Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.
    Cancer Cell, Vol. 11, No. 3. (March 2007), pp. 217-227.
    by CH Yun, TJ Boggon, Y Li, MS Woo, H Greulich, M Meyerson, MJ Eck
    posted to egfr inhibitor mutation review structure by pjasper on 2007-05-08 19:00:37 as ** along with 1 person and 1 group cursonivel1 cursonivel1
  • Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib.
    Exp Cell Res, Vol. 313, No. 7. (15 April 2007), pp. 1361-1372.
    by X Liu, DL Carlisle, MC Swick, A Gaither-Davis, JR Grandis, JM Siegfried
    posted to egfr gastrin iressa resistance by pjasper on 2007-05-08 18:59:54 as **
  • EGFR kinase domain mutations – functional impact and relevance for lung cancer therapy
    Oncogene, Vol. aop, No. current.
    by D Irmer, JO Funk, A Blaukat,
    posted to egfr mutation review by pjasper on 2007-05-08 18:59:01 as **
  • A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.
    Proc Natl Acad Sci U S A, Vol. 104, No. 10. (6 March 2007), pp. 4071-4076.
    by AM Scott, FT Lee, N Tebbutt, R Herbertson, SS Gill, Z Liu, E Skrinos, C Murone, TH Saunder, B Chappell, AT Papenfuss, AM Poon, W Hopkins, FE Smyth, D MacGregor, LM Cher, AA Jungbluth, MW Brechbiel, R Murphy, AW Burgess, EW Hoffman, TG Johns, LJ Old
    posted to ch806 egfr inhibitor by pjasper on 2007-05-08 18:57:28 as **
  • The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines.
    Histochem Cell Biol, Vol. 127, No. 5. (May 2007), pp. 541-553.
    by Y Nishimura, B Bereczky, M Ono
    posted to egfr internalization iressa by pjasper on 2007-05-08 18:56:46 as **
  • Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines.
    Clin Cancer Res, Vol. 13, No. 5. (1 March 2007), pp. 1552-1561.
    by J Kurai, H Chikumi, K Hashimoto, K Yamaguchi, A Yamasaki, T Sako, H Touge, H Makino, M Takata, M Miyata, M Nakamoto, N Burioka, E Shimizu
    posted to c225 egfr inhibitor by pjasper on 2007-05-08 18:55:26 as **
  • Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.
    Cancer Res, Vol. 67, No. 5. (1 March 2007), pp. 2046-2053.
    by T Okabe, I Okamoto, K Tamura, M Terashima, T Yoshida, T Satoh, M Takada, M Fukuoka, K Nakagawa
    posted to activation egfr mutation nsclc by pjasper on 2007-05-08 18:54:50 as **
  • Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.
    Cancer Res, Vol. 67, No. 5. (1 March 2007), pp. 2081-2088.
    by B Lutterbach, Q Zeng, LJ Davis, H Hatch, G Hang, NE Kohl, JB Gibbs, BS Pan
    posted to egfr met by pjasper on 2007-05-08 18:53:41 as **
  • Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.
    Cancer Res, Vol. 67, No. 5. (1 March 2007), pp. 2325-2330.
    by R Mulloy, A Ferrand, Y Kim, R Sordella, DW Bell, DA Haber, KS Anderson, J Settleman
    posted to egfr iressa mutation nsclc by pjasper on 2007-05-08 18:52:47 as **
  • Epidermal growth factor (EGF) receptor endocytosis is accompanied by reorganization of microtubule system in HeLa cells.
    Cell Biol Int, Vol. 31, No. 4. (April 2007), pp. 349-359.
    by MV Kharchenko, AA Aksyonov, MM Melikova, ES Kornilova
    posted to egfr internalization by pjasper on 2007-05-08 18:51:12 as **
  • HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
    Breast Cancer Research, Vol. 9 (02 March 2007), 205.
    by Neil Spector, Wenle Xia, Iman El-Hariry, Yossi Yarden, Sarah Bacus
    posted to erbb2 inhibitor by pjasper on 2007-05-08 18:50:28 as ** along with 1 person klu
  • Consequences of Direct Versus Indirect Activation of Epidermal Growth Factor Receptor in Intestinal Epithelial Cells Are Dictated by Protein-tyrosine Phosphatase 1B.
    J Biol Chem, Vol. 282, No. 18. (4 May 2007), pp. 13303-13315.
    by DF McCole, A Truong, M Bunz, KE Barrett
    posted to activation egfr phosphatase by pjasper on 2007-05-08 18:48:47 as **
  • Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy
    British Journal of Cancer, Vol. aop, No. current. (06 March 2007)
    by A Jimeno, P Kulesza, J Wheelhouse, A Chan, X Zhang, E Kincaid, R Chen, DP Clark, A Forastiere, M Hidalgo
    posted to egfr inhibitor mtor by pjasper on 2007-05-08 18:48:03 as **
  • Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.
    Ann Oncol, Vol. 18, No. 4. (April 2007), pp. 752-760.
    by F Hirsch, M Varella-Garcia, F Cappuzzo, J McCoy, L Bemis, A Xavier, R Dziadziuszko, P Gumerlock, K Chansky, H West, A Gazdar, L Crino, D Gandara, W Franklin, P Bunn
    posted to amplification egfr inhibitor iressa nsclc by pjasper on 2007-05-08 18:46:53 as **
  • Epidermal growth factor receptor mutations in lung cancer
    Nature Reviews Cancer, Vol. 7, No. 3., pp. 169-181.
    by Sreenath V Sharma, Daphne W Bell, Jeffrey Settleman, Daniel A Haber
    posted to egfr mutation nsclc review by pjasper on 2007-05-08 18:44:57 as ** along with 1 person kochhan
  • Spatial regulation of EGFR signaling by Sprouty2.
    Curr Biol, Vol. 17, No. 5. (6 March 2007), pp. 455-461.
    by HJ Kim, LJ Taylor, D Bar-Sagi
    posted to egfr sprouty by pjasper on 2007-05-08 18:43:53 as **
  • Dual silencing of the EGF and type 1 IGF receptors suggests dominance of IGF signaling in human breast cancer cells.
    Biochem Biophys Res Commun, Vol. 355, No. 3. (13 April 2007), pp. 700-706.
    by J Riedemann, M Sohail, VM Macaulay
    posted to breast egfr igf by pjasper on 2007-05-08 18:43:28 as **
    • NB: Du kan sitere denne siden som: http://www.citeulike.org/user/pjasper

    Result page: 1 2 3 4 5 6 Next RIS BibTeX RSS
    CiteULike organises scholarly (or academic) papers or literature and provides bibliographic (which means it makes bibliographies) for universities and higher education establishments. It helps undergraduates and postgraduates. People studying for PhDs or in postdoctoral (postdoc) positions. The service is similar in scope to EndNote or RefWorks or any other reference manager like BibTeX, but it is a social bookmarking service for scientists and humanities researchers.